Search results
2 Biotech Stocks to Buy in May
Motley Fool via Yahoo Finance· 10 hours agoThe stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that...
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
Zacks via Yahoo Finance· 6 months agoRegeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced positive study data on the...
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
Zacks via Yahoo Finance· 2 years agoSanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase...
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
Benzinga via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Phase 3 trial of Dupixent...
Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds
Zacks via Yahoo Finance· 2 years agoThis week, Merck MRK in-licensed co-development rights to Orion Corporation’s prostate cancer...
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
Zacks via Yahoo Finance· 4 months agoThe FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include...
Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent
Zacks via Yahoo Finance· 2 years agoRegeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug...
Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers
Investor's Business Daily· 7 months agoRegeneron Pharmaceuticals' high-dose Eylea is off to a strong start in the U.S., the company said...
US FDA approves Dupixent to treat younger kids with esophageal condition
Reuters via Yahoo News· 4 months ago(Reuters) -The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to...
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Zacks via Yahoo Finance· 1 year agoThis week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a...
